• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液恶性肿瘤患者行低强度预处理异基因造血干细胞移植的风险评估评分的预测价值。

Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation.

机构信息

Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.

出版信息

Am J Hematol. 2014 Sep;89(9):E138-41. doi: 10.1002/ajh.23764. Epub 2014 Jun 20.

DOI:10.1002/ajh.23764
PMID:24845702
Abstract

Reduced-intensity conditioning allogeneic stem cell transplantation (RIC allo-SCT) is associated with less toxicity and is used for older patients. We retrospectively studied the predictive value of two risk assessment scores, which were the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and the pre-transplantation assessment of mortality (PAM) score, for assessing the outcome of RIC allo-SCT. Seventy-eight patients underwent transplantation between 2005 and 2013 at a single institution. RIC was performed with fludarabine and melphalan with/without total body irradiation. The 3-year overall survival of patients with an HCT-CI >3 was significantly worse than that of patients with an HCT-CI 0-3 (31.6% vs. 59.6%, P = 0.020). Also, the 3-year overall survival of patients with a PAM score >24 was significantly worse than that of those with a PAM score ≤24 (29.2% vs. 61.4%, P = 0.005). The present findings suggest that changing the cut-off values of these risk assessment scores can improve prediction of outcomes in patients receiving RIC allo-SCT with this conditioning regimen and we need validation by large-scale study with other regimens.

摘要

降低强度预处理的异基因造血干细胞移植(RIC allo-SCT)相关毒性较低,用于老年患者。我们回顾性研究了两种风险评估评分的预测价值,即造血细胞移植特异性合并症指数(HCT-CI)和移植前死亡率评估(PAM)评分,用于评估 RIC allo-SCT 的结果。78 例患者于 2005 年至 2013 年在单中心接受移植。RIC 采用氟达拉滨和马法兰,联合/不联合全身照射。HCT-CI >3 的患者 3 年总生存率明显低于 HCT-CI 0-3 的患者(31.6%比 59.6%,P=0.020)。此外,PAM 评分>24 的患者 3 年总生存率明显低于 PAM 评分≤24 的患者(29.2%比 61.4%,P=0.005)。这些发现表明,改变这些风险评估评分的截止值可以改善该预处理方案的 RIC allo-SCT 患者的预后预测,我们需要用其他方案进行大规模研究验证。

相似文献

1
Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation.血液恶性肿瘤患者行低强度预处理异基因造血干细胞移植的风险评估评分的预测价值。
Am J Hematol. 2014 Sep;89(9):E138-41. doi: 10.1002/ajh.23764. Epub 2014 Jun 20.
2
Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.比较两种移植前预测模型和使用不同截断点的灵活 HCT-CI,以确定低、中、高危组:在接受 allo-RIC 的患者人群中,灵活 HCT-CI 是 NRM 和 OS 的最佳预测因子。
Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14.
3
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.两种标准的降低强度预处理方案和两种不同移植物来源在血液病成人患者异基因干细胞移植中的疗效比较:一项单中心分析。
Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.
4
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.氟达拉滨、卡莫司汀、马法兰和抗胸腺细胞球蛋白用于成人降低毒性预处理和同种异体干细胞移植:结果取决于疾病风险指数,但与年龄、合并症评分、供体类型或人类白细胞抗原错配无关。
Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7.
5
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.联合造血细胞移植合并症指数和欧洲血液与骨髓移植组评分可更好地对接受低强度异基因造血细胞移植的高危患者进行分层。
Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72. doi: 10.1016/j.bbmt.2013.10.011. Epub 2013 Oct 17.
6
Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.血液系统恶性肿瘤患者异基因干细胞移植的传统与降低强度预处理方案
Eur J Haematol. 2005 Feb;74(2):144-51. doi: 10.1111/j.1600-0609.2004.00360.x.
7
Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.高血清铁蛋白血症对降低强度预处理异基因造血细胞移植治疗淋巴恶性肿瘤结局的影响。
Biol Blood Marrow Transplant. 2013 Apr;19(4):597-601. doi: 10.1016/j.bbmt.2012.12.018. Epub 2013 Jan 8.
8
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.急性白血病患者 HLA 全相合同胞异基因造血干细胞移植中,减低剂量预处理方案与清髓性预处理方案的比较结果:单中心经验
Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.
9
Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience.异基因造血干细胞移植后,在儿童中采用低强度预处理方案:单中心经验。
Eur J Haematol. 2012 Jun;88(6):504-9. doi: 10.1111/j.1600-0609.2012.01776.x. Epub 2012 Mar 21.
10
Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.采用简化方法的难治性或复发性淋巴瘤患者门诊接受低强度异基因干细胞移植与自体干细胞移植的比较。
Ann Hematol. 2010 Oct;89(10):1045-52. doi: 10.1007/s00277-010-0986-1. Epub 2010 May 21.

引用本文的文献

1
External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.同种异体造血干细胞移植中多种预后评分的外部验证和比较。
Blood Adv. 2019 Jun 25;3(12):1881-1890. doi: 10.1182/bloodadvances.2019032268.
2
How I treat acute myeloid leukemia presenting with preexisting comorbidities.我如何治疗伴有基础合并症的急性髓系白血病。
Blood. 2016 Jul 28;128(4):488-96. doi: 10.1182/blood-2016-01-635060. Epub 2016 May 27.